Star products | only real biological glycosylated hemoglobin (HbA1c) test kit, help improve the level of diabetes diagnosis and treatment!
The latest data from the International Diabetes Federation (IDF) shows that 0.537 billion adults (20-79 years old) have diabetes-this number is expected to increase to 0.643 billion by 2030 and 0.783 billion by 2045.
The latest epidemiological survey data included in the 2020 version of the CDS guidelines show that according to the World Health Organization (WHO) standards, the prevalence of diabetes in my country has reached 11.2, of which type 2 diabetes accounts for more than 90%. As a big country of diabetes, China is facing many challenges in improving the level of diagnosis and treatment of diabetes.
On April 19, 2021, the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition) were officially released.Glycosylated hemoglobin (HbA1c)For the first time, it was included in the diagnostic criteria of type 2 diabetes in China, with HbA1c ≥ 6.5% as the cut-off point to assist in the diagnosis of diabetes.
How much do you know about hemoglobin A1c (HbA1c)?
What is HbA1c?
Glycosylated hemoglobin (HbA1c) is the product of the non-enzymatic reaction of the amino group of hemoglobin with glucose or other carbohydrate molecules.
The formation of HbA1c is proportional to the blood glucose concentration and the duration of the concentration of glucose. The higher the blood glucose concentration and the longer the duration, the higher the HbA1c content and the more the proportion in the total hemoglobin.
As a carrier of hemoglobin, the life span of red blood cells is 120 days. Therefore, HbA1c can indirectly reflect the average blood glucose level of patients in the past 3 months.
4 Clinical Implications of HbA1c
HbA1c can be seen in diabetes diagnostic criteria, control objectives, and clinical diagnosis and treatment pathways. Why is it so concerned? What are the clinical significance of monitoring HbA1c?
Used to assess the patient's average blood glucose level at 2 to 3 months
HbA1c has good stability, can accurately reflect the degree of long-term blood glucose control, and is not affected by the occasional increase or decrease of blood glucose. It can objectively reflect the average blood glucose level of diabetic patients in the past 2 to 3 months, and plays an important role in blood glucose monitoring.
As a diagnostic indicator of diabetes
As early as 2011, WHO recommended the use of HbA1c in the diagnosis of diabetes, but due to the large differences in the standardization of HbA1c determination in different regions of China, the diagnostic criteria have not yet been unified.
In the newly released Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition), HbA1c is officially included in the diagnostic criteria for diabetes. The Guidelines clearly state:In a laboratory with strict quality control, HbA1c measured by a standardized test can be used as a supplementary diagnostic standard for diabetes.
The complete diagnostic criteria for diabetes in the Guidelines are as follows:
Used to predict the risk of chronic complications of diabetes
The level of HbA1c is closely related to the occurrence of chronic complications of diabetes (especially microvascular complications). The higher the glycosylated hemoglobin, the greater the risk of complications.
Image source: Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)
used to evaluate the effectiveness of treatment regimens for glycemic control
HbA1c can sensitively reflect the effect of blood glucose control in diabetic patients, not only used as a diagnosis, but also as a key indicator of clinical follow-up.
If the patient's blood sugar control effect is not good, the body's glycosylated hemoglobin index concentration can rise to the normal level of 2 times or more. We often say that HbA1c is the gold standard for diabetes control. In clinical practice, the control level of HbA1c is also used as the basis for adjusting the treatment plan.
Only real biological help to improve the level of diabetes diagnosis and treatment
Early diagnosis, timely intervention, monitoring of long-term changes in blood glucose levels and control them within the ideal range are essential to delay the occurrence and development of diabetes complications and improve the overall diagnosis and treatment of diabetes.
Guangdong Weishi Biotechnology Co., Ltd. has always been committed to the innovative research and development of rapid diagnosis products for diabetes, and actively promotes the clinical value promotion and standardization process of HbA1c detection.
Guangdong only real biological glycosylated hemoglobin (HbA1c) detection kit (immunofluorescence method),5 minutes out of the results, high precision, simple operation, suitable for diabetes auxiliary diagnosis and blood glucose monitoring.
HbA1c detection kit (immunofluorescence method)
normal reference value
Guangdong Weishi biological HbA1c detection kit in clinical trials of excellent performance, the company's products and hospital laboratory Bio-Rad glycosylated hemoglobin A1c detection kit (HPLC method) parallel control test showed a good correlation, the correlation coefficient (r) is 0.9938. High, medium and low concentration levels of clinical samples in repetitive experiments, CV% were less than 5%.
In the future, Guangdong Weishi biology will continue to adhere to the development concept of "pursuing excellence, only truth and reality", contribute to improving the level of diabetes diagnosis and treatment, and let medical innovation benefit more patients!
 IDF Diabetes atlas 9th edition 2019. Retrieved Nov 18,2019, from https://www.diabetesatlas.org/en/
Diabetes Association of Chinese Medical Association. Guidelines for Prevention and Treatment of Type 2 Diabetes in China (2020 edition)[J]. Chinese Journal of Diabetes, 2021,13(4):315-409.
 Diabetes Society of Chinese Medical Association. Guidelines for Clinical Application of Blood Glucose Monitoring in China (2021 Edition). Chinese Journal of Diabetes, 2021, 13(10): 936-948.